ipharmacenter Consulting services

Eli Lilly has entered a definitive agreement to acquire Ventyx Biosciences in an all‑cash transaction valued at approximately 1.2 billion dollars, aiming to strengthen its position in orally delivered therapies for chronic, inflammation‑mediated diseases. Ventyx contributes a differentiated portfolio of small‑molecule oral candidates targeting autoimmune, inflammatory and neurodegenerative diseases, centered on NLRP3 inhibition and advanced IBD assets. iPharmaCenter Consultin

The European Commission has granted Marketing Authorisation to Johnson & Johnson for IMAAVY (nipocalimab), a novel FcRn-blocking antibody therapy designed to help people living with generalised myasthenia gravis (gMG). The approval covers both adult and adolescent patients aged 12 years and older who test positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibodies. gMG is a chronic autoimmune neuromuscular disorder that impairs communicati

Bristol Myers Squibb is extending enrollment in its pivotal ADEPT-2 Phase 3 trial of Cobenfy in psychosis associated with Alzheimer’s disease, following a review of site-level data and a recommendation from the study’s independent Data Monitoring Committee (DMC). The company remains blinded to efficacy and safety outcomes from the study.​ Also read: Top pharmaceutical companies by revenues | 2025   Study continuation after data review During a blinded quality review of ADEPT-

AbbVie has announced the approval of Aquipta (atogepant) by the European Commission for the preventive treatment of migraine in adults...

Recent data reveals that advances in NHS treatment have substantially improved the survival rates of babies born with spinal muscular...

EiSai and Biogen announced that Biologics License Application (BLA) for lecanemab received Priority Review in China. The National Medical...

October 10, 2022 UCB plans to release Briviact in Japan with an Asian study UCB announced the Phase 3 study results of Briviact...

October 12, 2022 AstraZeneca announced strong efficacy data of Ultomiris. AstraZeneca announced the results of the CHAMPION-NMOSD trial...